Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.

Employees

Sector

Biotechnology & Medical Research

More about the company

06-25	Incannex Healthcare Inc Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea	CI
06-25	Incannex Healthcare Receives US Patent for IHL-42X in Obstructive Sleep Apnea	MT

Market Cap	54.32M 37.93M 33.14M 30.59M 28.19M 53.14M 3.65B 366M 144M 1.79B 142M 139M 6.16B	P/E 2026 *	-2.04x	P/E 2027 *	-2.2x
Enterprise Value	54.32M 37.93M 33.14M 30.59M 28.19M 53.14M 3.65B 366M 144M 1.79B 142M 139M 6.16B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	87.66%	Yield 2026 *	-	Yield 2027 *	-

06-25	Incannex Healthcare Inc Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea	CI
06-25	Incannex Healthcare Receives US Patent for IHL-42X in Obstructive Sleep Apnea	MT
05-15	Tranche Update on Incannex Healthcare Inc.'s Equity Buyback Plan announced on August 22, 2025.	CI
05-15	Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
05-14	Incannex Healthcare commences Dreamzz clinical study of IHL-42X for obstructive sleep apnea	RE
05-14	Incannex Healthcare Inc Commences DReAMzz Clinical Study For IHL-42X In Obstructive Sleep Apnea	CI
04-22	Incannex Healthcare Inc. Announces Incannex?s Completed Phase 2 Clinical Trial, PSX-001 Demonstrated Statistically Significant and Clinically Meaningful Improvements Across All Primary and Secondary Endpoints	CI
03-27	Incannex reactivates share repurchase program, underscoring confidence in valuation and strategic position	RE
03-25	Incannex Healthcare Inc. Enters Partnership Agreement with American Academy of Sleep Medicine Foundation	CI
03-17	Incannex regains compliance with Nasdaq minimum bid price requirement	RE
03-13	Incannex Healthcare Inc. Strengthens Clinical Development Pathway For IHL-42X Following Positive Phase 2 Outcomes	CI
02-25	Incannex Healthcare approved 1-for-30 reverse stock split	RE
02-13	Tranche Update on Incannex Healthcare Inc.'s Equity Buyback Plan announced on August 22, 2025.	CI

06-25	Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea	AQ
06-10	Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility	AQ
06-09	Incannex Announces Initiation of Research Coverage by Alliance Global Partners	AQ
05-14	Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea	AQ
05-12	Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development	AQ

Manager	Title	Age	Since
Joel Latham CEO	Chief Executive Officer	37	01/01/2016
Joseph Swan DFI	Director of Finance/CFO	35	29/02/2024
Luigi Barbato CTO	Chief Tech/Sci/R&D Officer	63	21/10/2024

Mount Magnet South Ltd Stock Australian S.E.

Stocks

AU000000MUM1

Biotechnology & Medical Research

Valuation: Mount Magnet South Ltd

Latest news : Mount Magnet South Ltd

Analysts' recommendations: Mount Magnet South Ltd

Press Releases: Mount Magnet South Ltd

Managers and Directors: Mount Magnet South Ltd

Bio Therapeutic Drugs

Financials

Company Profile

End-of-day quote Australian S.E. Other stock markets
- ^AUD	-

Director	Title	Age	Since
Troy Valentine CHM	Chairman	52	01/11/2023
Peter Widdows BRD	Director/Board Member	60	01/11/2023
Joel Latham BRD	Director/Board Member	37	01/01/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+0.24%	-1.54%	+52.85%	+71.85%	53.83B
WUXI APPTEC CO., LTD.	-7.17%	-4.39%	+42.72%	+73.32%	52.1B
INSMED INCORPORATED	+0.80%	-6.31%	+5.62%	+417.78%	23.48B
BIONTECH SE	-0.09%	-0.01%	-16.85%	-15.41%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	-5.95%	-2.58%	+29.53%	-9.47%	19.36B
GENMAB A/S	-1.14%	+0.03%	+31.67%	-30.65%	17.56B
PHARMAESSENTIA CORPORATION	-5.16%	-7.00%	+168.44%	+314.96%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.91%	-5.83%	+25.17%	+644.30%	14.83B
EXELIXIS, INC.	+0.43%	-1.03%	+25.75%	+189.74%	14.06B
Average	-2.77%	-2.62%	+40.54%	+184.05%	25.95B
Weighted average by Cap.	-2.80%	-2.36%	+39.55%	+143.13%

	2026 *	2027 *
Net sales	-	-
Net income	-24.91M -17.4M -15.2M -14.03M -12.93M -24.37M -1.68B -168M -65.95M -821M -65.34M -63.9M -2.82B	-24.89M -17.38M -15.19M -14.01M -12.92M -24.35M -1.67B -167M -65.88M -820M -65.26M -63.83M -2.82B
Net Debt	-	-